TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

BACKGROUND: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general conditions and comorbidities, treatments’ objectives, and dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Cremolini, Chiara, Marmorino, Federica, Loupakis, Fotios, Masi, Gianluca, Antoniotti, Carlotta, Salvatore, Lisa, Schirripa, Marta, Boni, Luca, Zagonel, Vittorina, Lonardi, Sara, Aprile, Giuseppe, Tamburini, Emiliano, Ricci, Vincenzo, Ronzoni, Monica, Pietrantonio, Filippo, Valsuani, Chiara, Tomasello, Gianluca, Passardi, Alessandro, Allegrini, Giacomo, Di Donato, Samantha, Santini, Daniele, Falcone, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466800/
https://www.ncbi.nlm.nih.gov/pubmed/28599628
http://dx.doi.org/10.1186/s12885-017-3360-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466800/
https://www.ncbi.nlm.nih.gov/pubmed/28599628
http://dx.doi.org/10.1186/s12885-017-3360-z

Ejemplares similares